The executive branch is reconfiguring its approach to vetting individuals for access to sensitive information and granting them security clearances in an attempt to modernize and improve its procedures, according to a new quarterly report.
“The Insider Threat and Security Clearance Reform (ITSCR) Cross Agency Priority (CAP) Goals have been re-baselined so that they are aligned with the new enterprise-wide focus . . . and its four work streams (Trusted Workforce, Modern Vetting, Secure and Modern Mission-Capable IT, and Continuous Performance Improvement) for modernizing the SSC [security, suitability/fitness, and credentialing] mission over the next five years.” See the Quarterly Progress Update on Insider Threat and Security Clearance Reform, FY2016 Quarter 3, September 2016.
Translated out of bureaucratic jargon, this statement… still remains obscure and hard to understand. But at the least, it implies a determination that existing arrangements are unsatisfactory and that they require adjustment.
Among other steps, the latest Quarterly Update says that by December of this year, the Office of the Director of National Intelligence will “Establish a policy that requires the national security population to report information of security concern to the proper authorities in a timely manner.” The exact nature of such a requirement and its likely effect on “the national security population” remain to be seen.
Though security clearance “reform” of some kind has been underway for many years, the recent arrest of former NSA contractor Harold T. Martin III on suspicion of theft and retention of classified information suggests that room for improvement still exists. (“NSA case highlights growing concerns over insider threats” by Christian Davenport, Washington Post, October 6).
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
As the efficacy of environmental laws has waned, so has their durability. What was once a broadly shared goal – protecting Americans from environmental harm – is now a political football, with rules that whipsaw back and forth depending on who’s in charge.